Daratumumab and pomalidomide for multipel myeloma – pro
Daratumumab is a recently approved effective agent in multiple myeloma, and there is great interest in combining it with other effective agents. Amongst them is pomalidomide. A phase I study by Chari et al concluded that DARA to POM-Dexamethasone was well tolerated and did not result in additional toxicities with the exception of DARA-related infusion reactions. Deep and durable responses were observed quickly, along with a high response rate. Studies have shown that in the relapsed/refractory setting, pomalidomide and dexamethasone demonstrated an overall response rate (ORR) of 30%, while single-agent daratumumab elicited an ORR of 30% in a similar setting. Together, pomalidomide and daratumumab preliminarily demonstrated an ORR of approximately 70%, and a significant number of patients achieved a very good partial response. However, more studies need to be performed
Ajai Chari, Sagar Lonial, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Xiang Qin, Tara Masterson, Kerri Nottage, Jordan M Schecter, Tahamtan Ahmadi, Brendan Weiss, Amrita Krishnan, Suzanne Lentzsch, Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. Blood 2015 126:508;
Pomalidomide, Prescribing Information 2016
NCCN, Multiple Myeloma 2016